Back to search
BRCA1/2 Mutation
Clinical trial pipeline · Data from ClinicalTrials.gov
See which BRCA1/2 Mutation trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which BRCA1/2 Mutation trials you may qualify forThis is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day…
The project aims at enhancing performance metrics and prospectively validating a radiogenomics model based on ovarian US images for predicting germline breast c…
The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how peop…
The goal of this multi-center observational study is to learn about the effectiveness and safety of different prophylactic (preventive) surgical options in wome…
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients…
The goal of this clinical trial is to determine whether an adapted version of a current cognitive-behavioural group therapy (CBT) protocol for cancer survivors…
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment a…
The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men…